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the report is “Performance evaluation of GSK with a comparison of ratio analysis to few of the 
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regular process of talent attainment at GSK.  
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be a great achievement for me if you find this report informative enough to fulfill the 
requirements. I am really grateful to you. 
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Yours sincerely  
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Executive Summary  
 
GlaxoSmithKline started its journey in Bangladesh on the year 1949 as an importer of its own 
products and its importing activities used to hold in Chittagong but eventually it emerged its roles 
to manufacturing sector also and established factory in Chittagong. So, GSK is operating in 
Bangladesh for 63 years and it’s really providing excellent service in Consumer Healthcare and 
Pharmaceutical sector. GlaxoSmithKline has a strong Secretarial department which is working in 
line with the strategies of the organization and working with the aim of attaining the mission and 
vision of the company. GSK has mainly three divisions in HR department and these are HR 
development, HR services and administration. Under the HR department performance appraisal 
system takes place. A survey is conducted at corporate office of GSK to evaluate the appraisal 
system. The whole report is divided into six parts. First part comprises of introduction part which 
includes objectives, methodology, scope, limitations of the study, second part comprises of 
organizational overview which includes GSK worldwide to GSK Bangladesh. Moreover, third 
part comprises a briefing on practices as an intern, its activities, techniques, perceptual errors; 
fourth part comprises of the Function of Secretarial Department conducted at GSK Bangladesh 
and fifth part includes findings and analysis of the research conducted through my internship 
period and last part comprises conclusion and recommendation and its effective implementation. 
The internship report is made on financial performance comparison among GSK, Square and 
Beximco. The report includes the analyzing and evaluating company’s financial statements, 
because without this the ratio analysis it would be tough to find out the gsk’s current position in 
Bangladesh. 
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1.1. Introduction 
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare 
companies – is committed to improving the quality of human life by enabling people to do more, 
feel better and live longer. GlaxoSmithKline (GSK) is a world’s leading research based 
pharmaceutical company with a powerful combination of skills and resources that provides a 
platform for delivering strong growth in today’s rapidly changing healthcare environment. It 
provides significant information to identify and analyze the market need, market size and 
competition. This project is based on the information of Secretarial Department of 
GlaxoSmithKline, a pharmaceutical company, and its promotional activities and how more 
awareness can be created for the product in a most effective communicating way.It is the only 
British organization in the world’s top 20 pharmaceutical companies. Subsidiary companies are 
established over 50 countries of the world many with their own manufacturing facilities and the 
group have agency representation in more than 100 offices. GSK has leadership in four major 
therapeutic areas anti invectives, central nervous system (CNS) and respiratory & gastro intestinal 
metabolic. In addition it is a leader in the important areas of vaccines and has growing portfolio of 
oncology products. GSK supplies products to 140 global markets and has over 100,000 employees 
worldwide.GSK has 180 manufacturing site in 41 countries. There are about 450 generics 
registered in Bangladesh. Out of these 450 generics, 117 are in the controlled category i.e. in the 
essential drug list. The remaining 333 generics are in the decontrolled category, the total number 
of brands/items that are registered in Bangladesh is currently estimated to be 5,300, while the total 
number of dosage forms and strengths are 8,300. Bangladesh pharmaceutical industry is mainly 
dominated by domestic manufacturers. Bangladesh Pharmaceutical Industry is now heading 
towards self sufficiency in meeting the local demand. The industry is the second highest 
contributor to the national exchequer after garments, and it is the largest white collar intensive 
employment sector of the country. The top 12 leading pharmaceuticals company in Bangladesh 
including local and MNC’s are Square, Incepta Pharma,Beximco, Opsonin Pharma, Eskayef, 
Renata, A.C.I., Aristopharma, Drug International, Sanofi Aventis, GlaxoSmithKline. With an 
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enviable image and  reputation for the past 6 decades GlaxoSmithKline (GSK) Bangladesh 
Limited running its operation as a subsidiary of GlaxoSmithKline one of the world’s leading 
research based pharmaceutical and healthcare companies.GSK is at 3th position among top 12 
pharmaceuticals in Bangladesh. Relentless commitment, setting of standards of ethical standards 
and quality backed leading edge technology of the Company has built a strong relationship 
between the stakeholders and GSK Bangladesh. With the ever committed 701numbers of 
personnel all over the country GSK Bangladesh, which now comprises of both pharmaceutical and 
consumer healthcare products, continually strive to meet the organization’s mission. As a Finance 
major I have done internship under Secretarial Department of GSK and carried out internship 
report based on the topic Do more, feel better, live longer gsk Secretarial Practice of 
GlaxoSmithKline Bangladesh Limited. assigned by my academic supervisor Ms. Rahman Akhter. 
1.2 History 
Glaxo was founded in the 1850s as a general trading company in, New Zealand, by a Londoner, 
Joseph Nathan. In 1904 it began producing dried-milk baby food, first known as Defiance, then as 
Glaxo, under the slogan "Glaxo builds bonny babies". The Glaxo Laboratories sign is still visible 
(right) on what is now a car repair shop on the main street of Bunnythorpe.Glaxo Laboratories 
opened new units in London in 1935. The company bought two companies, Joseph Nathan in 
1947 and 1958 respectively. After the company bought Meyer Laboratories in 1978, it began to 
play an important role in the US market. In 1983 the American arm, Glaxo Inc., moved to 
Research Triangle Park (US headquarters/research) and Zebulon (US manufacturing) in North 
Carolina. Burroughs Welcome & Company was founded in 1880 in London by the American 
pharmacists Henry Wellcome and Silas Burroughs. The Welcome Tropical Research Laboratories 
opened in 1902. In 1959 the Wellcome Company bought Cooper, McDougall & Robertson Inc. to 
become more active in animal health. Glaxo and Burroughs Welcome merged in 1995 to form 
Glaxo Welcome. Glaxo restructured its R&D operation that year, cutting 10,000 jobs worldwide, 
closing its R&D facility in Bechenham, Kent, and opening a Medicines Research Centre in Steven 
age, Hertfordshire. Also that year, Glaxo Welcome acquired the California-basedAffymax, a 
leader in the field of combinatorial chemistry.  
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By 1999 Glaxo Wellcome had become the world's third-largest pharmaceutical company by 
revenues, with a global market share of around 4 per cent.Its products included. In 1999 the 
company was the world's largest manufacturer of drugs for the treatment of asthma and 
HIV/AIDS.It employed 59,000 people, including 13,400 in the UK, had 76 operating companies 
and 50 manufacturing facilities worldwide, and seven of its products were among the world's top 
50 best-selling pharmaceuticals. The company had R&D facilities in Hertfordshire, Kent and 
London, and manufacturing plants in Scotland and the north of England. It had R&D centers in 
the US and Japan, and production facilities in the US, Europe and the Far East 
GlaxoSmithKline(GSK) Bangladesh Limited carries with it an enviable image and reputation for 
the past 6 decades. A subsidiary of GlaxoSmithKline plc- one of the world's leading research-
based pharmaceutical and healthcare companies GSK Bangladesh, continues to be committed to 
improving the quality of human life by enabling people to do more, feel better and live longer. 
The Company’s principle activities include secondary manufacture of pharmaceutical 
products  and marketing of  vaccines, pharmaceutical healthcare products and health food drinks. 
In 1949 the Company commenced its journey in Bangladesh with its’ corporate identity as Glaxo 
in Chittagong as an importer of  products from the Glaxo Group Companies. It started spreading 
its spectrum from being an importer to  a manufacturer by establishing its own manufacturing unit 
at Chittagong in 1967. The facility till date is considered as one of the Centres of Excellence in 
Global Manufacturing & Supply Network of the Group.    The global corporate mergers and 
acquisitions has seen the evolution of the Company’s identity in the past 6 decades. In line with 
mergers and acquisitions the identity changed from Glaxo to Glaxo Wellcome Bangladesh 
Limited  following the Burroughs Welcome acquisition in 1995 and finally to GlaxoSmithKline 
Bangladesh Limited  during 2002 after merger with SmithKline Beecham in December 2000. The 
mega merger of the Company enables it to deliver cutting edge advancements in health care 
solutions. The relentless commitment, setting of standards of ethical standards and quality backed 
leading edge technology of the Company has built a strong relationship between the stakeholders 
and GSK Bangladesh. With the ever committed 615 numbers of personnel all over the country 
GSK Bangladesh, which now comprises of both Pharma and Consumer, continually strive to meet 
the GlaxoSmithKline mission to  improve the quality of human life  
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GSK is committed to developing new and effective healthcare solutions. The values on which the 
group was founded have always inspired growth and will continue to do so in times to come.   
1.3. Product offering 
Gsk  make a wide range of prescription medicines, vaccines and consumer healthcare products. 
They may list many products across a wide range of countries on the following pages.  The names 
of these products can vary by country, as can their indications for use.In March 2015 they 
completed a 3-part transaction with Novartis which reshapes business. As the integration of this 
business units progresses, GSK manufactures products for major disease areas such as asthma, 
cancer, infections, diabetes and mental health. Its biggest-selling in 2013 were Advair, Ayodat, 
Flovent, Augmentin, lovzana, and Lamictal; its drugs and vaccines earned £21.3 billion that year. 
Other top-selling products include its asthma nhalers Advair, Ventolin, and Flovent; its diphtheria, 
tetanus pertussis vaccine Infanrix and its hepatitis B vaccine; the antihyper lipemia drug Lovaza; 
and the antibacterial Augmentin .Medicines historically discovered or developed at GSK and its 
legacy companies and now sold as generics include amoxicillin[ and amoxicillin-caly,  ticarcillin-
clavulanate , mupirocin and ceftazidime  for bacterial infections, for HIV infection, for herpes 
virus infections, albendazole  for parasitic infections, sumatriptan  for unatemigraine, lamotrigine 
for epilepsy, bupropion and paroxetine for major depressive disorder, and cimetidine and 
ranitidine for gastroesophageal reflux disorder. Among these, amoxicillin, amoxicillin-
clavulanate, mupriocins, zidovudine, albendazole, and ranitidine are listed on the World Health 
Organization's list of essential medications.  
1.Medicines and vaccines  
Specific information on products in individual countries by choosing the relevant country from the 
menu below.Gsk  do not provide a comprehensive list of products but they  provide about 
prescription  medicines and vaccines.  
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2.Healthc are products  
Gsk has a legacy that goes back more than 160 years, producing some of the world’s best-loved 
healthcare brands including: Sensodyne, Voltaren, Theraflu, Parodontax, Panadol, Polident and 
Otrivin. These brands are successful in more than 100 countries, reflecting our passion for quality, 
backed by science. They are built around the needs of the millions of people who go online or 
walk into pharmacies, supermarkets and market stalls all over the world, every day and choose us 
first. Their brands are organized into five global categories: Pain Relief, Respiratory, Oral Health, 
Nutrition/Gastro Intestinal and Skin Health. These categories are defined by a specific consumer 
healthcare need and have complementary ranges of brands that allow us to evolve with our 
consumers’ needs. 
2. Oral Health Produc 
We are experts in specialist oral health, combining our unique understanding of consumer needs 
with science. For example, GSK’s Novamin technology, a world first, is the ingredient in 
Sensodyne that repairs and protects sensitive teeth by using the building blocks of teeth in the 
paste. 
 Sensodyne 
 Polident 
 Parodontax 
 Biotene 
 Aquafresh 
3.Nutrition Product 
We have a strong heritage in Nutrition. Horlicks, our largest brand, is consumed in 38 million 
homes in India (190 servings per second), contributing significantly to the malnutrition agenda.  In 
Gastro Intestinal, we have antacid brands such as Tums and Eno, which sold over 150 million 
sachets in Brazil in 2014.   
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 Horlicks 
 Eno 
 Tums 
 Skin Health 
We are a trusted leader in skin care, delivering innovative science-based products. Our brands 
include medicated skin products recommended by dermatologists, as well as specific treatments 
for cold sores, itchy skin and athlete’s foot.  
 Physiogel 
 Abreva 
 Zovirax 
 Lamisil 
 Fenistil 
4.ViiV Healthcare  
ViiV Healthcare is a global specialist HIV company dedicated to delivering advances in treatment 
and care for people living with HIV. We are an independent pharmaceutical company established 
in 2009 by combining the power and expertise in the management of HIV from both GSK and 
Pfizer. Following a long-term collaboration on the joint development of several novel integrate 
inhibitors we were joined by Shionogi in 2012. 
Our current portfolio of eleven HIV treatments generated annual sales of £1.5 billion in 2014 
providing us with the financial stability to take a sustainable, long-term view when investing in 
our pipeline of new medicines. Our scientists are 100% dedicated to finding new ways to limit the 
impact of HIV on the 35 million people living with the virus and understanding how best to 
prevent and treat the disease. Our dedicated staff of almost 550 people is located in 16 countries 
and three regional hubs and we extend this geographical reach still further via our relationship 
with GSK. We are equipped to move quickly in response to the needs of the HIV community and 
have launched industry-leading access initiatives to help deliver on WHO/UNAIDS goals to reach 
all those who need treatment.  
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In addition, we actively support community initiatives in HIV, including the Positive Action 
programmed, by partnering with like-minded organizations that share our ethos. 
5. Stiefel dermatology  
Stiefel has a long history of excellence in dermatology and deep expertise and R&D capabilities in 
acne, psoriasis, eczema, atopic dermatitis and superficial skin infections. Our portfolio ranges 
from prescription to daily skincare, so that we can offer quality, science-led products that help 
meet individual treatment needs and improve overall quality of life for people with skin 
conditions. 
1.3.1.Product overview: 
 
1. Pharmaceuticals:  
 
GSK’s board pharmaceuticals product line includes antibiotic, antidepressant, gastrointestinal, 
dermatological, respiration, cancer and cardiovascular medications. GSK has a variety of vaccine 
products, including hepatitis A and B, diphtheria, tetanus, whooping cough and influenza.  
 
2. Consumer Healthcare:  
 
GSK Consumer Health brings oral health care, over the counter medicines and nutritional health 
care products to millions of people.  
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GlaxoSmithKline Products Glossary 
  
 
  60 products including 
  Berin 
 
Local production 
Cytamen 
 Kefdrin 
  Pentamox 
   
  17 products including 
 
Imported product 
Alkeran 
 
Seretide   
  Zinnat 
   
  17 products including 
 
Vaccines 
Engerix-B 
 
  Fluarix   
  Synflorix 
   
  9 products including 
  Horlicks 
  Chocolate Horlicks 
 
Consumer Healthcare 
Junior horlicks 
 
Mother Horlicks   
  Horlicks Lite 
  Boost 
  Maltova 
  Glaxose 
   
 
          Table : GSK Product Glossar*(Source: Marketing department GSK, Bangladesh) 
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1.4.Operational network organogram 
GlaxoSmithKline Bangladesh Limited is operated by the Board of Directors and the Company 
Executive Committee (CEC). 
The Board of Directors is ultimately accountable for the Company's activities, strategy and 
financial performance.  
A) Board of Directors and           B)Company Executive Committee 
Operational network is organized and managed  along with the Chairman and directors. Under 
the board of directors there are two non- Executive Directors. Whole structure of this board is 
given in below including everyone’s name and designation. 
Mr Rodrigo Becker Chairman,SVP Area Head, Africa and Developing 
Countries 
 
M. Azizul Huq 
Managing Director , GSK Bangladesh 
 
 Mr. Fayekuzzuman 
Non-Executive Director & Member, Audit  
Committee  
Managing Director, Investment Corporation of  
Bangladesh 
 
 
 
Zinnia Huq 
Finance Director & Company Secretary 
GSK Bangladesh 
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 Masud Khan
Non-Executive Director
Chairman, Audit Committee 
 
 
  Rajib Barua 
Site Director, GMS Chittagong 
 
 
Gopalakrishnan Venkatramani 
General Manager  
Consumer Healthcare 
Managing 
1.5.Organizational structure of Company 
 
1.5.1 Top Management 
 
As per provisions of the Article of Association, Board of Directors holds periodic meetings to 
resolve issue of policies and strategies, recording minutes/decisions for implementation by the 
Executive Management. 
 
1.5.2 Executive Management 
 
The Managing Director heads the Executive Management, the Chief Executive Officer (CEO) 
who has been delegated necessary and adequate authority by the Board of Directors. The 
Executive Management operates through further delegations of authority at every echelon of the 
line management. 
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1.5.3 Corporate Governance Structure: 
 
 
                                              
                                            Corporate Governance Structure 
 
 
 
 
       Board of Directors Executive Committee Audit Committee 
 
 
                   Figure : GSK corporate governance structure 
 
 1.5.4. Others network 
Total number of products: 86 
 No. of manufacturing products in Bangladesh: 50 
 District Marketing Offices (DMO’s): Total no of DMO’s are 11 around the country 
1.5.5.Operations in Bangladesh 
GlaxoSmithKline Bangladesh Limited has twelve District Marketing Offices (DMO) throughout 
the country. These are divided in five zones by which GSK’s products are sold. 
District Marketing Offices: GSK has 12 District Marketing Offices (DMO) in Bangladesh. The 
locations of DMOs are shown below- 
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 Zone                   DMO      
   
 Dhaka Dhaka, Mymensing 
   
 Chittagong Chittagong, Maijdee 
   
 Comilla Comilla, Sylhet 
 Bogra Bogra, Rajshahi, Rangpur 
   
 Khulna Khulna, Jessore 
 Barisal Barisal 
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1.6. Vision for the future 
1.6.1.Vision: 
A vision articulates the position that an organization would like to attain in the distant future. 
Vision therefore is future aspirations that lead to an inspiration to be the best in one’s field of 
activity. Visions are inspiring and exhilarating. It creates a common identity and a shared sense 
of purpose. They are competitive, unique and simple. Good visions foster risk-taking and 
experimentation. They represent integrity. The vision of GlaxoSmithKline (GSK) is for their 
value chain to be carbon neutral by 2050.  
1.6.2.Mission 
Its global quest is to improve the quality of human life by enabling people do more, feel better, 
and live longer. The business is focused around the delivery of three strategic priorities which 
aim to increase growth, reduce risk and improve our long-term financial performance.  
1.6.4. Value 
Gsk has  changed their R&D organization so that it is better able to sustain a pipeline of products 
that offer valuable improvements in treatment for patients and healthcare providers. 
This is underpinned by a focus on improving productivity and rates of return in R&DTheirs 
business is focused around the delivery of three strategic priorities which aim to increase growth, 
reduce risk and improve our long-term financial performance. These priorities are: grow a 
diversified global business, deliver more products of value, and simplify the operating model. 
Strategic goals and aims These are the more finely focused statements of intent directed at those 
aspects of the organization’s operations which are critical to success – often described as ‘the 
core business.  
1.7. Objective of the project 
1.7.1. Origin of the Report: 
The major objective of this report is the partial fulfillment of the requirements of internship 
program of BBA Program at Independent University, Bangladesh. Fortunately GSK management 
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has assigned this topic “Motivate the employee for higher productivity” to fulfill the partial 
requirement of my internship. 
 1.7.2. Objective: 
The main objectives of this project were- 
 1. To understand the existing productivity of GlaxoSmithKline in production department. 
 Regression 
 2. To find out the present state of motivation of the GSK employees for higher productivity. 
My objective behind doing this research is — 
1. To find what GSK employee value as motivators. 
 2. How the employees rank the existing facilities offered by GSK. 
To come out with the possible outcomes to increase motivation among the GSK employees, this 
will lead GSK Bangladesh LTD towards higher productivity. 
1.8. Methodology 
For the purpose of preparing the report more meaningful and presentable, two sources of data 
and information are used widely. Both primary and secondary data sources are used to prepare 
this report. There are some records collected from various resources of the company. 
1.8.1 Selection of the Theme: My supervisor assigned the topic of the study. Before the topic 
was assigned it was thoroughly discussed so that, a well-organized internship report can be 
prepared. 
1.8.2 Sources of Data 
To carry out the study both primary and secondary data were used. 
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1.8.2.a) Primary Sources 
To collect all these data, I had to commence an interview with the Finance Manager & 
Secretarial Executive who could give the actual information that was required to prepare an 
authentic report. Personal observation plays a big role to make the report perfect. 
1.8.2.b) Secondary Sources 
Referring to the secondary sources I mainly used the web site of GlaxoSmithKline Bangladesh 
Ltd. and also other reports of GSK so that I could manage to study on the purpose of preparing 
the report. 
1.9. Limitation of the Study 
It should be noted that the study was subject to certain limitations.The authority of 
GlaxoSmithKline Bangladesh Limited was so busy in my internship period that they could not 
provide enough time for me despite their frantic effort. 
1. Due to time constraint, I could not make the report a more detailed one. 
 
2. Lack of previous literature and scarcity of other secondary information. 
 
3. Study on Secretarial practice needs lots of deskwork which also needs huge time so lack of 
proper time was also one of the major limitations. 
 
4. Respondent’s unwillingness/ hesitation on providing confidential information. They felt they 
are leaking out some information, which they are not supposed to. 
 
5. Authority was not available as they had to maintain a lots work. 
 
Although there were many limitations I tried to give my best effort to furnish the report. 
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Chapter-2 
            Job Description 
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2.1. Job Description at GSK 
Secretarial department one of the major department in Gsk. It main tasks is to handle the 
payment issues of the employees. This includes all the employees in both corporate office and 
Factory site and also includes the DMOs. Secretarial department keeps record of all the 
employees thus any payment issue can have the proper evidence which will help both the 
company and employees in future to negotiate properly. 
Secretarial department keeps contact with banks for different transaction purposes and time to 
time collect the information about deposits and withdrawals about the accounts like Pension 
Fund, Dividend Payment, Provident Fund, Treasury Bills etc.The department handles the issues 
like purchasing and encashment of Treasury Bills, providing the bonus payments and recording 
the loan payments given to the employees. Secretarial department also handles the allowance 
issue that is given to the interns and that’s why they keep information of all interns thus payment 
can be made on right time. 
This department continuously plays an vital role as they  keep contacts with the Central Bank, 
Security and the Exchange commission and the Dhaka Stock exchange regarding the audit 
issues, compliance concerns and stock market operations. They have the proper right to judge 
that the expense claim is valid or not and on this issue the secretarial department’s decision is 
final. They also keep records of foreign travel bills.  
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2.2.Specific Responsibilities of the jobs as an Intern 
I have launched my internship program in Glaxosmithkline on June 22,2015.From that day 
my responsibilities has been started. My supervisor Mr. Nizam Uddin sir who is a Deputy 
Company Secretary  has provided opportunity to understand the different activities of 
Secretarial Department. While doing the internship program, so far the activities I did and the 
activities I learned from asking others from my curiosity referring from the other departments 
than that off Accounts and Finance Department, I have tried my level best to acquire 
knowledge regarding my job responsibilities and also for other activities.My specific 
responsibilities are discussed in below: 
2.2.1 About secretarial function 
At the very beginning my interest was to know the file settlement of the Department through 
the hard and soft copy file list. The name of the files and in which drawer it’s kept up. 
2.2.2 Verifying the expense claims 
Every month, GSK confronts with a numerous numbers of expense claims which GSK is 
supposed to disburse as per company policy. The policy refers theses payments as allowance 
to the employees. There are two types of expense claims and those are: 
a) Travelling Expense 
b) Medical Expense 
This is what something which is allowed for all the employees including Corporate Office, 
GMS Factory and DMO or field as well. But in terms of medical policy, GSK’s allowance is 
available for the employee’s spouse and children as well up to a certain age until or unless 
he/ she is not a minor. There are some costs which are known as Remuneration which are 
allowed for the Managers of the Corporate Office and DMO. Aside from these remunerations 
the Directors are the main receiver of the remuneration from the company. The claims are 
supposed to be verified with priority basis in every month as it is an audit issue. Throughout 
the month I checked these travelling and medical bills collected from throughout the country. 
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2.2.3 Verifying T &E Forms 
The expense claims of the Corporate Office and GMS factory are supposed to be sent 
through T&E Forms. This form allows employees to place their claims for further approval 
from their Bosses and as soon as the Boss gives the approval, Secretarial Legal Department 
goes for further processing. I checked this T & E forms bills for salary payments at each 
month. 
2.2.4. Data Entry 
At the end of the month, I had to input the data in the excel sheet. Where all the record of 
medical claims and travelling expense were included. Apart from this, I had to wrote 
shareholder’s record for dividend warrant of the current year. Many others data I had input.  
2.2.5. Final Settlements File 
If any of the employees leave GSK or gets terminated by GSK, Secretarial Department 
arranges a document known as Final Settlement Copy, which refers to keep the document as 
evidence for both the parties acknowledging that GSK don’t have any claim with the person 
any more neither do the party. I had to punch the documents and make files provided by our 
supervisor. 
2.2.6Know how to use photocopy machine: 
Secretarial Department plays big roles to keep the sensitive information of the employees. 
High secrecy is maintained here. For this, maximum time I had to make a photocopy of those 
documents. By this time I also know the basic function of using the machine. 
2.2.7.Data entry: 
The bills which have been checked like travelling, medicals are needed to put the data into 
Excel worksheet. In addition many others data entry were taken place by me. 
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2.2.8.Uses of Microsoft word and Excel Worksheet 
Mostly I haves prepared letter of application for the Securities Exchange as well as for the 
different organization. On the other hand, much other information like Motor cycle related 
information also need to entry into the Excel sheet. 
2.2.9.Preparing Files and folders 
Most of the times I prepared personal files. These personal files were needed to make by name 
and employee Company code. I also separated the bills with folder like Chittagong GMS bills 
and Corporate Officers bills. 
2.3. Different Aspect of Job Performance 
Besides the Secretarial Department I have done various Job performance which was fallen under 
other aspects. All of these are discussed in below. 
 In part of Secretarial Department my core task was checking  and verifying the expense 
claims of the DMOs. I used to follow the company rules while deciding that the expense 
claim is valid or not. 
 Apart from checking and verifying all the expenses bills. I had to input the entries in the 
system and then also used to check that all valid payments have got clearance. If there were 
any difficulties or confusions then I used to inform the Secretarial Executive. 
 Maximum officially authorized issues were handled by them so   huge files categorized and 
organized by me where all the files were kept in sequence. 
 This department needs to contact with different institutions and individuals, in this regard 
sometimes I used to type different sorts of business letters. 
 As the department accomplishes the payroll activities, so employees used to visit the 
department for payment purposes and in absence of supervisors, I used to attend them, then 
used to convey their messages and claims to my supervisors.  
 The Secretarial department taught me to be prompt, sincere, honest, active, efficient and most 
importantly it taught me how to communicate in the corporate world. For enhancing these 
abilities in me and for providing me such a sophisticated environment, I will be ever grateful 
to GSK and specially the Secretarial department. 
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 At present month, mostly  crucial task was according to the shareholder’s addresses, serially 
putting the annual reports in envelopes and then keeping records that how much annual 
reports have been sent to the shareholders and how much is remaining In addition these I had 
also done some other major and minor tasks. Overall, I am spending a very busy schedule in 
GSK but it was full of fun and it also helped me a lot to know the core official jobs.  
 
2.4. Critical observation and recommendation 
2.4. a) Critical observation 
2.4. 1.Troubles were observed in the organization 
As my  internship period was actually 3 month times. Within this time I have faced several 
problems regarding this work. My obstacles were mentioned in below that seemed as troubles to 
me. 
 Office hour normally 8:30 A.M. To 5:00 P.M. being a student it’s hard to work 
such long time. Most of the time, I had to stay 6.00p.m.  
 Sometimes officers don’t want to give the responsibility types work to the 
internee. 
 Sometimes all of the offices are too busy to talk, so at the end it’s tough to learn. 
 Sometimes officers give odd job like filling, arrangement file, stapling etc. 
 The information was not sufficient in website. Sometimes, they do not want to  answer some 
question as these may be their trade secret. 
 GSK Bangladesh truly follows the code of conducts which established by its parent 
company. All the employees here try to maintain integrity in their every tasks.  
 All the departments are here properly co-ordinate which fosters the organizational 
performance a lot. Here the importance of human asset is truly realized and all the employees 
are believed as the heart of the organization and that’s why the employees work here with 
true motivation and sincerity.  
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 In Finance department, I found that employees of this department are very much 
knowledgeable and skilled and very efficiently they plan and implement the financial 
strategies. They are also very much. 
 
2.4. b).Recommendation 
 Should add a new subject on different function of an Organization in university major 
course. 
 Faculties should have been  shared in practical example in the context of our own 
Departmental function. 
 Make student familiar with some Activities related software use and its implication.  
 Make student familiar with different practical practices of an Organization. 
 GSK should concentrate more on promotional activities and making people more aware 
about their company profile and products thus a strong brand image can be established. 
 They should  use strong privacy for several agreements. 
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3.1.SWOT Analysis of GSK 
 
GSK performs SWOT analysis to assess its strengths, weaknesses, opportunities and threats. 
3.1.1. Strengths 
Good Acquaintances: one of the major strength of GlaxoSmithKline Bangladesh Limited is 
its financial feedback and back up as it is the 2nd ranked pharmaceutical company in the 
world. As it has offices and plants in different leading countries so the firm has never 
suffered from any financial crisis. 
Well-known Multinational in the pharmaceutical industries sector: GlaxoSmithKline 
Bangladesh limited is an emerging company in the pharmaceutical industries sector. For its 
multidimensional concept in the context of Bangladesh, it drew the attention of people very 
quickly and with in a short period of time it has gotten a wide range of customer base. 
Efficient Performance: GlaxoSmithKline provides hassle free customer service to its 
customer base comparing to the other pharmaceutical companies of Bangladesh. The 
Company’s motto is to take personalized approach to the need of the customers. 
Enthusiastic Workforce: The selection and recruitment of GlaxoSmithKline Bangladesh 
Limited emphasizes on having the skilled graduates and postgraduates who have 
backgrounds or job experience for that particular job. The logic behind is that
GlaxoSmithKline wants to avoid the problem of garbage in and garbage out. These type 
young and fresh workers stimulate the whole working environment of 
GlaxoSmithKline. 
Empowered Work Force: The human resource of GlaxoSmithKline is extremely well 
thought and perfectly managed .As from the very first the top management believed in 
empowered employees. This empowered environment makes GlaxoSmithKline 
Bangladesh Limited a better place for the employees. The employees aren’t suffocated 
with authority but are able to grow as the organization matures. They feel proud to be a 
part of the organization. 
Equalization: At GlaxoSmithKline Bangladesh Limited, workshops are conducted 
periodically. In the workshops, all the executives participate as equals; the executives 
are free to challenge top managers with ideas openly. 
Distinct Operating procedures: GlaxoSmithKline Bangladesh has distinct operating 
procedures. Production capacity and demand of customers are assessed by 
GlaxoSmithKline helps to decide how much to produce with in a one business year. 
 Distinct Schedule: Everyone in the GlaxoSmithKline Bangladesh Limited from the 
appraiser to top management has to work to the same schedule toward a different aspect 
of the same goal, interfacing simultaneously at all level over quite a long period of time.  
Training and educational program for all employee: To ensure the supremely 
GlaxoSmithKline always arrange training and educational programs for continuous up 
gradation for their employees  
 3.1.2.Weakness 
Raw material restrictions:  GlaxoSmithKline just cannot use raw materials from any 
source though it might be cheaper than present source. 
Prolong decision making: As GSK is a  world leader research based multinational 
company so to a certain extent they cannot compete with the local pharmaceutical 
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company in Bangladesh because for GSK it needs to under go at least 5-6 years 
extensive research to lunch a new product. 
Lower degree of customer’s Confidence: To the citizens of Bangladesh, 
GlaxoSmithKline is not uniquely dominated in the field of pharmaceutical industry. 
Additionally because of the dominant existence of Square, Beximco pharma people are 
indifferent in buying medicine from GlaxoSmithKline Bangladesh Limited after 
providing the highest quality products. So existence of the giant competitor 
GlaxoSmithKline business growth is in under pressure. 
3.1.3.Opportunities 
High Demand of Quality Medicines: Next to fooding, clothing and housing, health 
treatment is a basic need of people. The most important thing of a human being is his or 
her health. Since health treatment is one of the basic needs of people, there is always a 
high demand of quality medicines, the prime output of GlaxoSmithKline. 
Absence of Substitute products: As GlaxoSmithKline is the world’s best research 
based pharmaceutical company so continuously it has coming up with lot of innovations 
and inventions. So considering these new products local pharmaceutical companies are 
totally unmatched with the GlaxoSmithKline regarding innovations and inventions. 
A Strong Network: One of the major positive aspects of GlaxoSmithKline Bangladesh 
Limited is its worldwide network. Established of different R&D, biotechnology, clinical 
development, actives supply, product supply and management know-how in different 
countries facilitate to run the whole operation efficiently. 
Contract Manufacturing: Speed of implementation at contractor site is faster then in-
house and cheaper as the GlaxoSmithKline Bangladesh limited doesn’t have to invest 
huge amount to install machines and support systems to produce those products. . 
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3.1.4.Threats 
Pricing: As GlaxoSmithKline Bangladesh Ltd ensures High quality product and raw 
materials, so its products price is comparatively high then other local brands. Due to this 
reason Present customers are switching over to other local brands like Beximco pharma, 
Square Pharma etc. 
Ethical Standard: Company ethical issues are so sound that GSK cannot perform any 
unethical task to manage drug administration and other tribulations to maximize profit. 
Bangladesh Government’s regulation: Government regulation can be a big threat, if 
the government implements restriction to the multinationals to improve the local 
national pharmaceutical brands. 
3.2.Ratio Analysis 
1. Current Ratio 
Current ratio = current assets / current liabilities 
 
Year 2010 2011 2012 2013 2014 
Ratio 1.25 1.08 0.99 1.11 1.104 
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From the figure e can see in last five years gsk current ratio has been changed. From 
2010 to 2014 it has been fallen down a little bit. In 2010 they have more current asset 
compare to current liability. Again from 2013 o 2014 current ratio has been declined 
shortly. Because in 2013, they have more asset then liability. But in 2014 they have 
liability for that current ratio was less. 
2.Qucik Ratio 
Quick Ratio=(Current assets - Inventory)/current liabilities 
Year 2010 2011 2012 2013 2014 
 
Ratio 0.92 0.74 0.67 0.79 0.66 
 
 
From the graph it iis visible that gsk has lowest quick ratio on 2014 where it was 
highest in 2010.Always a high quick ratio is not considered as good, if it happens that 
the firm has huge account receivables but those will be collected after a long time and 
the current liabilities are lesser but needs to be paid instantly then the quick ratio will 
be higher but still the firm is in a great risk as there is liquidity crisis. So, their 
liability was increasing compare to previous year. Apart from the inventory their 
current asset was not sufficient to increase the quick ratio. 
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3.Cash Ratio 
(Cash+Marketable Securities)-Notes Payable/Current Liability 
Year 2010 2011 2012 2013 2014 
 
Ratio 0.49 0.39 0.31 0.41 0.33 
 
 
Here, Gsk has shown almost similar outcome like as previous. Because they have more 
liability on 2014 compare to 2010.Thougth they try to manage cash and maintain 
marketable securities for the purpose of increasing cash ratio.However, in this ratio their 
ratio were fallen down. 
4.Return on Equity 
 
Return on Equity =Net Income/ Shareholder's Equity 
 
Year 2010 2011 2012 2013 2014 
 
Ratio 29.7 19.83 16.42 29.51 35.69 
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Gsk has a good return of equity in 2014.Compared to the last five years, in 2014 they 
have highest return on equity. Because of higher income, they were able to earn such 
value. Though their ROE were fallen on 2012 but for high revenue and income they 
have overcome this and were able to bring a good percentage in terms of  ROE. Most 
important thing is that their shareholder’s equity were also decreasing. 
5. Net Asset Per Share 
Net Asset Per Share = Net Asset Value/No of Share  Outstanding 
Year 2010 2011 2012 2013 2014 
 
Ratio 114.65 118.07 123.66 153.66 192.3 
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An expression for net asset value that represents a fund's (mutual, exchange-traded, and 
closed-end) or a company's value per share. It is calculated by dividing the total net 
asset value of the fund or company by the number of shares outstanding. If we focused 
on the graph, we can easily predict that gsk’s net asset per share were high in 2014 
which was almost 192.3 on the other hand it was very less in 2010 which was only 
114.65.So, they were able to increase their net asset value and also decreased  number 
of share outstanding. 
6.Market Price Per Share 
Market Price Per Share= Market Value per Share / Earnings per Share 
 
Year 2010 2011 2012 2013 2014 
 
Ratio 10.15 17.77 21.63 16.08 12.72 
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If we look up at the back, gsk market share has been reduced a lot from 2011 to 2014.It 
was very high in 2012.On the other hand it was reducing in 2013 and 2014.Because in 
2014 they have increased their EPS as a result their overall market share has been 
declined. In terms of EPS market share is quite low in 2014. 
7.Dividend Per Share 
Dividend Per Share=  Dividends/No of Share 
Year 2010 2011 2012 2013 2014 
 
Ratio 20 15 15 15 19 
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Dividend per share has promoted as per company policy. Previously gsk gave less 
dividend compared to 2014.In 2014 their dividend per share is 19 which is really good 
and they also reduced their number of share. At present their market share price is also 
increasing. If we  focused on last three years their dividend was constant. So, this ratio  
was moving forward then previous record. 
8.Retrun on Asset (ROA) 
ROE= Net Income/Total Asset 
Year 2010 2011 2012 2013 2014 
Ratio 9.39 8.24 12.58 10.36 10.28 
 
 
In the figure the Return on Asset was high in 2010.After that, ROA was not increasing 
because they buy asset for which their total asset amount were increased. Though their 
total income was becoming high, they have asset also. Most important and latest data 
for ROA is  20% according to June 20, 2015. 
 
 
 
0
2
4
6
8
10
12
14
2008 2010 2012 2014 2016
8. Return on Asset
8.Return on Asset
 
 
 
Do more, feel better, live longer ‐  gsk 
 
41 
 
9. Earnings Per Share (EPS) 
EPS=Net Income/No of outstanding Common Stock 
 
Year 2010 2011 2012 2013 2014 
 
Ratio 34.05 23.41 20.25 45.35 68.63 
 
. 
Earnings per share of gsk is really impressive from the last 5 years. On 2014, their  EPS 
was 68.63 which has indicated that gsk  has increased Total income a lot on the other 
way they also maintained a good  revenue and profit. Although in 2012, EPS was very 
low because of Low income, however now their share price per share is also increased.  
 10.Inventory Turnover 
 Inventory Turnover = Cost of Goods Sold/Average Inventory 
Year 2010 2011 2012 2013 2014 
 
Ratio 6.87 5.95 7.48 8.67 8.92 
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In the figure, inventory turnover was high in 2014.Actually it was staying in similar 
position from 2013 to 2014.Because  their cost of goods sold was gradually increasing 
whereas turnover on inventory was no much .So, overall they have a little bit high 
turnover in 2014 compared to 2011.As day by day they have produced more products so 
total number of goods sold has been increased 
11.Total Asset Turnover 
Total Asset Turnover  =  Net Sales/Total Asset 
 
Year 2010 2011 2012 2013 2014 
 
Ratio 1.7 1.81 1.86 1.67 1.65 
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From 2013 to 2014 gsk has decreased both sales and asset. As a result ratio regarding 
total asset turnover has been increase. Basically they have a plan to increase their 
product line  for that they buy huge amount of assets and also increased sales volume. 
On an impact of this their total asset  turnover has been fallen down. 
12.Fixed Asset Turnover 
Fixed Asset Turnover = Sales/Fixed Asset 
Year 2010 2011 2012 2013 2014 
 
Ratio 9.31 9.85 11.16 12.39 12.89 
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In terms of  fixed asset turnover, gsk  has a good observation. AS their fixed asset has 
been increased from 2010 to 2014.to increase their sales and market share they have 
bought assets in which fixed asset was also remained, overall they have increased their 
fixed asset volume in 2013 to 2014.they have a big budget for this fixed asset. 
 
13.Debt to Asset Ratio 
     Debt to Asset Ratio    = Total Debt/ Total Asset 
Year 2010 2011 2012 2013 2014 
 
Ratio 0.37 0.35 0.39 0.32 0.28 
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This ratio finds out how much of the total asset is funded through debt. A debt ratio 
greater than 1 indicates that a company has more debt than assets and it is more 
dependent to its creditors for necessary financing. Meanwhile, a debt ratio of less than 1 
indicates that a company has more assets than debt. The higher this ratio, the more 
leveraged the company and the greater its financial risk. Although higher debt is not a 
problem if interest payments are made on time, but if it is not then definitely a great risk 
for the firm.Gsk was able to reduce their debt amount whereas they also increased their 
total asset amount in 2014.so their debt to asset ratio has been reduced. 
14.Debt to Equity Ratio 
Debt to Equity Ratio = Total Debt/ Total Equity 
Year 2010 2011 2012 2013 2014 
 
Ratio 0.59 0.60 1.06 1.1 1.16 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
2009 2010 2011 2012 2013 2014 2015
13.Debt to Asset Ratio
13.Debt to Asset Ratio
 
 
 
Do more, feel better, live longer ‐  gsk 
 
46 
 
 
The trend from graph shows that, GSK is gradually having an increase in its debt 
financing. In 2013 and 2014, it is even higher than 1 which is a matter of concern as 
they are relying more on external lenders and it can be a threat if interest rate increases. 
As they have reducing their equity amount so their debt o to equity has been gradually 
improving from 2012 to 2014. 
15.Times Interest Ratio 
Times Interest Ratio = EBIT/Interest Change 
Year 2010 2011 2012 2013 2014 
 
Ratio 674.1 123.8 79.5 75.23 85.23 
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Gsk is in improving position in terms of EBIT.Where they have less interest change. So 
as an impact on times to interest ratio was increased from 2013 to 201.which was 
almost 85.23%. it happened  because their earning was increased overall interest was 
not much high compared to sales. So they have developed in interest ratio. 
16.Gross Profit Margin     
Gross Profit Margin    = Profit/Sales 
Year 2010 2011 2012 2013 2014 
 
Ratio 34.2 28.4 28.61 32.67 39.42 
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A ratio of profitability calculated as net income divided by revenues, or net profit 
divided by sales. It measures how much out of every dollar of sales a company actually 
earns. This is also known as profit margin. Higher the profit margin, better the condition 
of the firm. Higher profit margin means that higher portion is remaining as profit after 
the selling activity takes place. So it also indicates towards efficient expense controlling 
ability. Increased earnings are good, but an increase in sales does not mean that the 
profit margin of a company is improving. For instance, if a company has costs that have 
increased at a greater rate than sales, it leads to a lower profit margin. This is an 
indication that costs need to be under better control. Total income gsk has increased as 
their product volume is creased  from the last few years. 
17.Net Profit Margin 
Net Profit Margin  =    Net Income/Revenue 
Year 2010 2011 2012 2013 2014 
 
Ratio 0.11 0.06 0.06 0.1 0.15 
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A ratio of profitability calculated as net income divided by revenues, or net profit 
divided by sales. It measures how much out of every dollar of sales a company actually 
earns. This is also known as profit margin. Higher the profit margin, better the condition 
of the firm. Higher profit margin means that higher portion is remaining as profit after 
the selling activity takes place. So it also indicates towards efficient expense controlling 
ability. Increased earnings are good, but an increase in sales does not mean that the 
profit margin of a company is improving. For instance, if a company has costs that have 
increased at a greater rate than sales, it leads to a lower profit margin. This is an 
indication that costs need to be under better control. Total income gsk has increased as 
their product volume is creased  from the last few years. 
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3.3.Competitve Analysis 
To Understand the  Gsk. market position, I have analyzed with few pharmaceutical 
companies in terms of  Quick ratio, Current Ratio, ROE, ROA, EPS from 2012 to 2014 . 
1.Current Ratio 
Current ratio: Current Asset/Current Liabilities 
Company Name 2012 2013 2014 
Gsk 0.99 1.11 1.104 
Square 1.58 1.62 2.27 
Beximco 2.67 2.72 2.82 
 
 
It is a liquidity ratio that measures a company's ability to pay short-term debts. The ratio 
is mainly used to give an idea of the company's ability to pay back its short-term 
liabilities (debt and payables) with its short-term assets (cash, inventory, receivables). 
The higher the current ratio, the more capable the company is of paying its obligations. 
Gsk ratio has increased from 2013 to 2014 that means they have problem regarding 
working capital management. Square and beximco has higher current ratio compared to 
gsk, so they also faced problem. On the other hand, if the current ratio is too high then it 
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indicates that the firm has problem in working capital management. Low current ratio 
does not always mean that the firm is at an alarming stage or very near to be bankrupt 
but of course it is better to maintain a standard current ratio in order to be free from 
liquidity risk. 
2. Quick Ratio 
Quick Ratio: (Current Assets-Inventories) ⁄ Current Liabilities 
Company Name 2012 2013 2014 
Gsk 0.67 0.79 0.66 
Square 0.92 1.13 1.26 
Beximco 1.88 1.79 1.74 
 
 
This ratio assesses the capacity of an organization to recover its current liabilities by 
using the organization’s quick assets. Assets which can be easily converted into cash 
are known as quick assets. Quick ratio is also known as Acid-test ratio and it 
excludes the inventories as inventories are less liquid. Quick ratio less than 1 
indicates that the firm is currently unable to pay its current debts. The graph shows 
that GSK Bangladesh has low quick ratio compared to 2013. The ratio was less than 
1 which was not pleasing. However, Square and Bexinco is more than 1 which  
indicate that their liquid assets are  high , their illiquid assts are very low. So, they 
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have a good quick ratio. The graph also shows that, GSK has low ratios because 
they are buying new products for which they have debt. For submitting this debt 
amount their asset amount is not  good but they have huge fixed asset.  So in quick 
ratio Beximco is in a good position as they have huge current assets. 
3.ROE 
Return on Equity: Net Income/Shareholders' equity 
Company name 2012 2013 2014 
Square 17.19 19.2 22.3 
Beximco 7.17 7.6 7.3 
Gsk 16.42 29.51 35.69 
 
 
Return on Equity or ROE is the ratio of net income to total shareholder’s equity. It 
measures how much a firm earns from the shareholders’ equity. It also shows the 
firm’s efficiency at generating profits from every dollar of equity capital. Increasing 
ROE indicates improved performance.GSK had the highest return on equity from 
2013-2014 compared to its competitors. So, it generated the highest return from their 
shareholders’ equity. On the other hand, Beximco has very low returns comparatively 
to Square and Gsk.  
 
0
5
10
15
20
25
30
35
40
2012 2013 2014
Square
Gsk
Beximco
 
 
 
Do more, feel better, live longer ‐  gsk 
 
53 
 
4.ROA 
Return on Asset: Net Income/Total Assets 
Company Name 2012 2013 2014 
Gsk 12.58 10.36 10.28 
Square 13.82 10.01 8.1 
Beximco 5.37 9.71 11.09 
 
 
 
The graph interprets that, GSK ROA was decreased from 2013 to 2014.as their total 
asset was increased. But Square’s trend shows that its performance was in stable 
position though it was also reducing. Beximco is the highest in 2014 compared to its 
competitors. It indicates that they are generating lowest amount of return from their 
investments in assets. Compared to other companies in the industry, GSK should focus 
on increasing their Return on asset. 
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5.EPS 
EPS (Earning Per Share): Net Income/No. of shares outstanding 
 EPS( Year)   
Company Name 2012 2013 2014 
Gsk 20.25 45.35 68.63 
Square 9.01 2.51 3.28 
Beximco 4.33 5.39 7.13 
 
 
Earnings per share or EPS express the earned profit against each share. It is considered 
as an important tool while measuring a company’s stock performance. Investors often 
judge firms with the EPS and always prefer a high EPS. However, always high EPS 
does not mean that the firm is doing well because the net income can be manipulative 
which makes the EPS overestimated. In the graph, it is shown that Gsk EPS is much 
higher then Square and Beximco. Again Square has low EPS compared to Beximco an 
gsk.But gsk EPS is getting higher from 2012 to 2014. 
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3.4. Market Position of GSK  
From the ratio analysis I have generated the percentage of these three pharmaceutical 
companies in term of market share. These percentages are given in below:  
Company Name Market Share ( Year 2015) 
GSK 30  % 
Square 19.21% 
Beximco 18.70% 
 
 
 
I 
In the figure Gsk Market share is the highest in terms of pharma.Compared to square 
and Beximco, Gsk market share  is much high. As Gsk is producing the medical product 
in a high rate. For example, Vaccine, Tablet and other drugs are made by Gsk. These 
Medical Drugs which are mentioned earlier. For all this Gsk market share is quite good 
in Bangladesh. 
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Chapter 6 
Recommendation and 
Conclusion 
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6.1.Recommendation 
Being a multinational company, at present GSK is earning revenue both for selling 
medicinal products and consumer goods. However, compared to its sales of medicinal 
products, consumer products like- Horlicks, Sensodyne etc. products have much 
demand. Thus, the revenue earned from consumer products are more compared to 
pharmaceutical products. This has diluted the position of GSK in the pharmaceutical 
industry. So, they should try more to give the same effort to promote their 
pharmaceutical products for earning greater revenues from this industry and compete 
successfully with their competitors, grabbing a strong market share and market position. 
 First recommendation regarding ratio analysis which depends on their balance sheet 
from last 5 to 6 years .According to analysis  GSK must concentrate on this issue 
and should  be careful to control the debts.   
 As a global  leader GSK company is committed  to improving the quality of service 
of Secretarial department. 
  Secretarial Department needs to recognize the perfect File list as hard and soft 
copy. 
 To reduce the work pressure they should recruit an employee. 
 Company should have strong and strict policy to overcome the cheating in bills and 
claims. Moreover, if there is a strong and strict policy employee never thinks to 
have fake bills and claims. 
 To reduce the communication gap each and every employee should have  a proper 
training of communication skills. It will help to run the Secretarial Department 
effectively.  
 Secretarial Department should focus and give emphasize for having a strong 
Information Technology Department to support them properly as it is their day to 
day concern. 
To set up a strong position Gsk should be concerned and taken the recommendation 
steps immediately 
 
 
 
 
Do more, feel better, live longer ‐  gsk 
 
58 
 
6.2.Conclusion 
Financial ratios analysis is a part of financial statement analysis and through this we can 
have knowledge about the company’s past and present performance. GlaxoSmithKline 
Bangladesh Limited is the largest and leading company in the pharmaceuticals industry 
for more than four decades by manufacturing quality product. It diversified in different 
area and sector of the local business field. The Company always concerns with the 
quality of the product or medicine for the customer and also increases the profit for its 
shareholder and stockholder and also the employees. They have a challenging and 
inspiring mission to improve the quality of human life by enabling people to do more, 
feel better and live longer. Most importantly it gives us an idea that what can be the 
company’s performance in the future. Ratio analysis involves the calculation of 
statistical relationship between data and it is a very popular technique of financial 
statement analysis. Throughout my analysis, I came to know about the financial 
strength, operational efficacy and management efficacy of GSK. I have realized that 
GSK is performing well, it is financially solvents but there some threats which are 
increasing recently. Compare to the last few years, the performance is going high. 
Gsk is improving in terms of market share and share prices. At present their market 
share is more than 85% which indicates a good sign for the company’s development.
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Appendix A 
Ratio Analysis for Performance Evaluation ( Amount in Taka)   
Name of Ratio Formula 2010 2011 2012 2013 2014 
1.Current Ratio Current assets / current 
liabilities 
1.25 1.08 0.99 1.11 1.104 
2.Quick Ratio (Current assets - 
Inventory)/current 
liabilities 
0.92 0.74 0.67 0.79 0.66 
3.Cash Ratio (Cash Market Securities)-
Notes Payable/Current 
Liability 
0.49 0.39 0.31 0.41 0.33 
4.Return on 
Equity 
Net Income/ Shareholder's 
Equity 
29.7 19.83 16.42 29.51 35.69 
5.Net Asset Per 
share 
Net Asset Value/No of 
Share Outstanding 
114.65 118.07 123.66 153.66 192.3 
6.Market Price 
Per Share 
Market Value per Share / 
Earnings per Share 
10.15 17.77 21.63 16.08 12.72 
7.Dividend Per 
share 
Dividends/No of Share 20 15 15 15 19 
8.Return on Asset Net Income/ Total Asset 9.39 8.24 12.58 10.36 10.28 
9.Earning Per 
Share (EPS) 
Net Income/No of 
outstanding Common Stock 
34.05 23.41 20.25 45.35 68.63 
10.Inventory 
Turnover 
Cost of Goods 
Sold/Average Inventory 
6.87 5.95 7.48 8.67 8.92 
11.Total Asset 
Turnover 
Net Sales/Total Asset 1.64 1.7 1.81 1.86 1.65 
12.Fixed Asset 
Turnover 
Sales/Fixed Asset 9.31 9.85 11.16 12.39 12.89 
 
 
 
Do more, feel better, live longer ‐  gsk 
 
61 
 
13.Debt to Asset 
Ratio 
Total Debt/ Total Asset 0.37 0.35 0.39 0.32 0.28 
14.Debt to Equity 
Ratio 
Total Debt/ Total Equity 0.59 0.6 1.06 1.1 1.16 
15.Times Interest 
Ratio 
EBIT/Interest Change 674.1 123.8 79.5 75.23 85.23 
16.Gross Profit 
Margin 
Profit/Sales 34.2 28.4 28.61 32.67 39.42 
17.Net Profit 
Margin 
Net Income/Revenue 0.11 0.06 0.06 0.1 0.15 
 
Appendix B 
 
  Current Ratio ( Year) 
Company Name 2012 2013 2014 
Gsk 0.99 1.11 1.104 
Square 1.58 1.62 1.64 
Beximco 2.67 2.72 2.82 
  Quick Ratio ( Year) 
Company Name 2012 2013 2014 
Gsk 0.67 0.79 0.66 
Square 0.92 1.13 1.26 
Beximco 1.88 1.79 1.74 
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  ROE( Year) 
Company Name 2012 2013 2014 
Gsk 17.19 19.2 22.3 
Square 7.17 7.6 7.3 
Beximco 16.42 29.51 35.69 
  ROA ( Year) 
Company Name 2012 2013 2014 
Gsk 12.58 10.36 10.28 
Square 13.82 10.01 8.1 
Beximco 5.37 9.71 11.09 
  EPS( Year) 
Company Name 2012 2013 2014 
Gsk 20.25 45.35 68.63 
Square 9.01 2.51 3.28 
Beximco 4.33 5.39 7.13 
 
Appendix C 
Market Position of GSK  
Company Name ( Year 2015) 
GSK 30% 
Square 19.21% 
Beximco 18.70% 
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List of Abbreviations  
 
MNC= Multinational company   
GSK= GlaxoSmithKline   
LTD= Limited   
PLC= Public limited company  
CEO= Chief Executive Officer  
PDP= Performance Development Plan  
 MBO=Management by Objectives  
 GMS= Global Manufacturing Supply  
HRP= Human Resource Planning   
R & D= Research and development  
 HR= Human Resources  
 HRD= Human Resources development  
HRM= Human Resource Management  
 DMO= District marketing offices  
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